Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Collaboration streamlines patient access to oncology clinical trials
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Subscribe To Our Newsletter & Stay Updated
